Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 13/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572273 | 0.89 | PTGES (0.45) | PTGESPPARGPPARA | |
| SCHEMBL4107237 | 0.84 | PTPN11 (0.50) | PTGESPPARGPPARAMCL1PTPN11 | |
| SCHEMBL4228390 | 0.83 | PPARG (0.50) | PTGESPPARGPPARA | |
| SCHEMBL4227238 | 0.83 | PTGES (0.41) | PTGESPPARGPPARACYP1A2 | |
| SCHEMBL4265118 | 0.83 | PTGES (0.46) | PTGESPPARGPPARAMCL1BCL2 | |
| SCHEMBL4090259 | 0.81 | PTGES (0.61) | PTGESCYP1A2MCL1PTPN11BCL2 | |
| SCHEMBL4916822 | 0.81 | PPARG (0.47) | PPARGPPARA | |
| SCHEMBL4095194 | 0.81 | PTPN11 (0.41) | PTGESPPARGPPARAMCL1PTPN11 | |
| SCHEMBL4913507 | 0.81 | PPARG (0.45) | PTGESPPARGPPARA | |
| SCHEMBL4922040 | 0.81 | PPARG (0.46) | PTGESPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTGES 47/4885PPARG 1316/4885PPARA 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.